SEC Contract Filing

Filing Date: 2019-12-05

Document Content:
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>ex10-23.htm
<DESCRIPTION>SIXTEENTH AMENDMENT TO MODIFICATION AGREEMENT
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0; text-align: left"><A HREF="crvw-8k_120319.htm">CAREVIEW COMMUNICATIONS, INC. 8-K</A></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT 10.23&nbsp;</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIXTEENTH
AMENDMENT TO MODIFICATION AGREEMENT</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
SIXTEENTH AMENDMENT TO MODIFICATION AGREEMENT (this &ldquo;<B><I>Amendment</I></B>&rdquo;) is made and entered into as of <B>November
29, 2019 </B>(the &ldquo;<B><I>Amendment Effective Date</I></B>&rdquo;), by and among CAREVIEW COMMUNICATIONS, INC., a Nevada
corporation (&ldquo;<B><I>Holdings</I></B>&rdquo;), CAREVIEW COMMUNICATIONS, INC., a Texas corporation and a wholly owned subsidiary
of Holdings (the &ldquo;<B><I>Borrower</I></B>&rdquo;), CAREVIEW OPERATIONS, L.L.C., a Texas limited liability company (the &ldquo;<B><I>Subsidiary
Guarantor</I></B>&rdquo;), and PDL INVESTMENT HOLDINGS, LLC (as assignee of PDL BioPharma, Inc.), a Delaware limited liability
company (both in its capacity as the lender (&ldquo;<B><I>Lender</I></B>&rdquo;) and in its capacity as Agent (solely in such
capacity as Agent, the &ldquo;<B><I>Agent</I></B>&rdquo;)) under the Credit Agreement (as defined below).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to that certain Credit Agreement dated as of June 26, 2015, among Holdings, the Borrower, the Lender and the
Agent (as amended, supplemented or modified as of the date hereof (the &ldquo;<B><I>Credit Agreement</I></B>&rdquo;), including
pursuant to that certain First Amendment to Credit Agreement dated as of October 7, 2015, that certain Modification Agreement
dated as of February 2, 2018 (the &ldquo;<B><I>Modification Agreement</I></B>&rdquo;), that certain Second Amendment to Credit
Agreement dated as of February 23, 2018 (the &ldquo;<B><I>Second Amendment</I></B>&rdquo;), that certain Amendment to Modification
Agreement dated as of May 31, 2018 (the &ldquo;<B><I>First Modification Amendment</I></B>&rdquo;), that certain Second Amendment
to Modification Agreement dated as of June 14, 2018 (the &ldquo;<B><I>Second Modification Amendment</I></B>&rdquo;), that certain
Third Amendment to Modification Agreement dated as of June 28, 2018 (the &ldquo;<B><I>Third Modification Amendment</I></B>&rdquo;),
that certain Third Amendment to Credit Agreement dated as of July&nbsp;13, 2018, that certain Fourth Amendment to Modification
Agreement dated as of August 31, 2018 (the &ldquo;<B><I>Fourth Modification Amendment</I></B>&rdquo;), that certain Fifth Amendment
to Modification Agreement dated as of September 28, 2018 (the &ldquo;<B><I>Fifth Modification Amendment</I></B><I>&rdquo;</I>),
that certain Sixth Amendment to Modification Agreement dated as of November 12, 2018 (the &ldquo;<B><I>Sixth Modification Amendment</I></B><I>&rdquo;</I>),
that certain Seventh Amendment to Modification Agreement dated as of November 19, 2018 (the &ldquo;<B><I>Seventh Modification
Amendment</I></B><I>&rdquo;</I>), that certain Eighth Amendment to Modification Agreement dated as of December 3, 2018 (the &ldquo;<B><I>Eighth
Modification Amendment</I></B><I>&rdquo;</I>), that certain Ninth Amendment to Modification Agreement dated as of December 17,
2018 (the &ldquo;<B><I>Ninth Modification Amendment</I></B>&rdquo;), that certain Tenth Amendment to Modification Agreement dated
as of January 31, 2019 (the &ldquo;<B><I>Tenth Modification Amendment</I></B>&rdquo;), that certain Eleventh Amendment to Modification
Agreement dated as of February 28, 2019 (the &ldquo;<B><I>Eleventh Modification Amendment</I></B>&rdquo;), that certain Twelfth
Amendment to Modification Agreement dated as of March 29, 2019 (the &ldquo;<B><I>Twelfth Modification Amendment</I></B>&rdquo;),
that certain Fourth Amendment to Credit Agreement dated as of April&nbsp;9, 2019, that certain Thirteenth Amendment to Modification
Agreement dated as of April&nbsp;29, 2019 (the &ldquo;<B><I>Thirteenth Modification Amendment</I></B>&rdquo;), that certain Fifth
Amendment to Credit Agreement dated as of May&nbsp;15, 2019, that certain Fourteenth Amendment to Modification Agreement dated
as of May&nbsp;15, 2019 (the &ldquo;<B><I>Fourteenth Modification Amendment</I></B>&rdquo;) and that certain Fifteenth Amendment
to Modification Agreement dated as of September&nbsp;30, 2019 (the &ldquo;<B><I>Fifteenth Modification Amendment</I></B>&rdquo;);
capitalized terms used and not defined in this Amendment shall have the meaning set forth in the Credit Agreement.</FONT></P>

<P STYLE="font: 12pt Times New Roman, T